Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.
Altmann
K H
KH
Ciba-Geigy Ltd., Central Research Laboratories, Basel, Switzerland.
Fabbro
D
D
Dean
N M
NM
Geiger
T
T
Monia
B P
BP
Müller
M
M
Nicklin
P
P
D000818:Animals; D001483:Base Sequence; D015195:Drug Design; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D009374:Neoplasms, Experimental / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000235:genetics / Q000494:pharmacology*; D011493:Protein Kinase C / Q000235:genetics; D051571:Protein Kinase C-alpha; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019908:Proto-Oncogene Proteins c-raf; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016914:Ribonuclease H / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D013329:Structure-Activity Relationship
D007527:Isoenzymes; D016376:Oligonucleotides, Antisense; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D017346:Protein Serine-Threonine Kinases; D019908:Proto-Oncogene Proteins c-raf; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha; D016914:Ribonuclease H